Matthias Pinter
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis 66
- Liver Disease and Transplantation 55
- Hepatitis C virus research 18
- Epidemiology top 1%
- Liver Disease Diagnosis and Treatment 62
- Cancer Research top 2%
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 14
- Colorectal Cancer Treatments and Studies 10
-
- Cancer Mechanisms and Therapy 14
-
- Organ Transplantation Techniques and Outcomes 11
- Co-authors
- Markus Peck‐RadosavljevicMichael TraunerRakesh K. JainWolfgang SieghartBernhard ScheinerThomas ReibergerChristian MüllerFlorian Hucke
- Journals
- Journal of Hepatology (21 papers)Alimentary Pharmacology & Therapeutics (9 papers)Journal of Clinical Oncology (9 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Matthias Pinter
140 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Hepatology 2.9k
- Epidemiology 2.1k
- Cancer Research 646
- Oncology 1.1k
- Pathology and Forensic Medicine 625
Countries citing papers authored by Matthias Pinter
This map shows the geographic impact of Matthias Pinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Pinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Pinter more than expected).
Fields of papers citing papers by Matthias Pinter
This network shows the impact of papers produced by Matthias Pinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Pinter. The network helps show where Matthias Pinter may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Matthias Pinter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 0 | |
| 5 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.breakdown → | 2024 | 75 |
| 6 | 2024 | 19 | |
| 7 | 2024 | 3 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 5 | |
| 10 | 2022 | 57 | |
| 11 | 2021 | 20 | |
| 12 | 2021 | 7 | |
| 13 | 2020 | 52 | |
| 14 | 2020 | 58 | |
| 15 | 2019 | 10 | |
| 16 | 2018 | 6 | |
| 17 | 2018 | 51 | |
| 18 | 2018 | 121 | |
| 19 | 2014 | 26 | |
| 20 | 2012 | 228 |
About Matthias Pinter
Matthias Pinter is a scholar working on Hepatology, Epidemiology, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 156 papers that have together received 4.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (66 papers), Liver Disease Diagnosis and Treatment (62 papers), Liver Disease and Transplantation (55 papers), Hepatitis C virus research (18 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer Mechanisms and Therapy (14 papers), Organ Transplantation Techniques and Outcomes (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). The work is most often cited by research in Hepatology (2.9k citations), Epidemiology (2.1k citations), Cancer Research (646 citations), Oncology (1.1k citations) and Pathology and Forensic Medicine (625 citations). Matthias Pinter has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Markus Peck‐Radosavljevic, Michael Trauner, Rakesh K. Jain, Wolfgang Sieghart, Bernhard Scheiner, Thomas Reiberger, Christian Müller, Florian Hucke, Ivo Graziadei and Wolfgang Vogel. Their work appears in journals such as Journal of Hepatology, Alimentary Pharmacology & Therapeutics, Journal of Clinical Oncology, United European Gastroenterology Journal and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.